AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00262470
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 0.05-0.3 mg PO x 1 dose
Trial: NCT00262470
Drug: Entacapone
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone 200-400 mg PO x 1 dose
Trial: NCT00262470
Drug: Entacapone & Propranolol
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Trial: NCT00262470
Drug: Atomoxetine & Propranolol
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Trial: NCT00262470
Drug: Mecamylamine
RxNorm normalized name: Mecamylamine
DrugBank: Mecamylamine (DB00657)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mecamylamine 1.25-5 mg PO x 1 dose
Trial: NCT00262470
Drug: Isosorbide Dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 5-20 mg PO x 1 dose
Trial: NCT00262470
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: midodrine 2.5-10 mg PO x 1 dose
Trial: NCT00262470
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: modafinil 100-200 mg PO x 1 dose
Trial: NCT00262470
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: octreotide 12.5-50 mcg Subcutaneous x 1 dose
Trial: NCT00262470
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol 10-80 mg PO x 1-2 dose
Trial: NCT00262470
Drug: Modafinil & Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
Trial: NCT00262470
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sertraline 25-50 mg PO x 1 dose
Trial: NCT00262470
Drug: memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: memantine 5-20 mg PO x 1 dose
Trial: NCT01619137
Drug: water and soap
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water and soap for 6-8 hours per day.
Trial: NCT01619137
Drug: Povidone-iodine And normal salin treatment
RxNorm normalized name: Povidone-Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
Trial: NCT01245543
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
Trial: NCT02977611
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose will be infused at dose of 500 mg over a one hour period
Trial: NCT03492671
Drug: Gemcitabine 1000 mg
RxNorm normalized name: gemcitabine 1000 MG
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
Trial: NCT03492671
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
Trial: NCT02197286
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule containing 4,000 IU of Cholecalciferol, per day
Trial: NCT03589326
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ponatinib Tablets.
Trial: NCT03589326
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib Tablets.
Trial: NCT03589326
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine IV injection.
Trial: NCT03589326
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone Tablets.
Trial: NCT03589326
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine IV infusion.
Trial: NCT03589326
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone Tablets.
Trial: NCT02179970
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
Trial: NCT04667975
Drug: CKD-702
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.
Trial: NCT02955472
Drug: GLA5PR GLARS-NF3 tablet 150mg
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A new formulation(3rd.) of Pregabalin CR tablet
Trial: NCT02955472
Drug: GLA5PR GLARS-NF1 tablet 150mg
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A new formulation(1st.) of Pregabalin CR tablet
Trial: NCT00987870
Drug: BFH772
RxNorm normalized name: BFH772
DrugBank: BFH772 (DB16035)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00987870
Drug: calcipotriol/betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03435952
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.
Trial: NCT02222233
Drug: BI 671800 HEA delayed release (enteric coated) tablet
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02222233
Drug: BI 671800 HEA solution
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02222233
Drug: BI 671800 HEA particulate
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00595517
Drug: Esomeprazole 20 mg
RxNorm normalized name: esomeprazole 20 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg once daily
Trial: NCT02349919
Drug: Procaterol
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
Trial: NCT01658124
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01788189
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00817557
Drug: Loteprednol
RxNorm normalized name: Loteprednol
DrugBank: Loteprednol (DB00873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory
Trial: NCT01850147
Drug: Sunitinib, chemotherapy
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
Trial: NCT02569437
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
Trial: NCT02569437
Drug: nasal saline spray
RxNorm normalized name: sodium chloride Nasal Spray [Simply Saline]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nasal saline sprays: 2 sprays each nostril three times a day
Trial: NCT02569437
Drug: Flonase
RxNorm normalized name: Flonase
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
Trial: NCT02569437
Drug: sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill to match doxycycline
Trial: NCT00438737
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00141245
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00589381
Drug: fenretinide lipid matrix
RxNorm normalized name: Matrix
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02949193
Drug: evogliptin
RxNorm normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg
Trial: NCT02949193
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
Trial: NCT01919684
Drug: LGD-6972
RxNorm normalized name: LGD-6972
DrugBank: LGD-6972 (DB14779)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01754961
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 500,000 IU given orally on Day 1
Trial: NCT02342197
Drug: Decapeptyl
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: half the dose of Gn agonist
Trial: NCT00502892
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg/m\^2 IV Daily x 3 Days
Trial: NCT00502892
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.8 grams/m\^2 IV Over 1 Hour x 5 Days
Trial: NCT00502892
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days \[for patients \> 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days\]
Trial: NCT00287989
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00287989
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg
Trial: NCT00287989
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg/m2
Trial: NCT00287989
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1500mg
Trial: NCT00489229
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00489229
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01846429
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
Trial: NCT00199706
Drug: 7.2% NaCl in 6% hydroxyethyl starch solution
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01227603
Drug: Nifedipine-candesartan FDC (BAY 98-7106)
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
Trial: NCT01227603
Drug: Nifedipine GITS (Adalat LA, BAYA1040)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1 tablet of nifedipine GITS 60 mg
Trial: NCT01227603
Drug: Candesartan (Atacand)
RxNorm normalized name: candesartan Oral Tablet [Atacand]
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
Trial: NCT01550484
Drug: 18F-AV-133
RxNorm normalized name: 18F-AV-133
DrugBank: Florbenazine F-18 (DB14945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 222 MBq (6 mCi)
Trial: NCT00908089
Drug: Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
Trial: NCT00202345
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00199797
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.
Trial: NCT00199797
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.
Trial: NCT01098656
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.~Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)
Trial: NCT04569422
Drug: Benoxyl
RxNorm normalized name: Benoxyl
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: reduce pain
Trial: NCT00032136
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00032136
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00442260
Drug: DOXIL
RxNorm normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00442260
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00660075
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg/d for 6 weeks
Trial: NCT00435279
Drug: Eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone 3 mg
Trial: NCT00435279
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
Trial: NCT01265602
Drug: vehicle of LAS41007
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
Trial: NCT00418366
Drug: MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00006398
Drug: Timolol Maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03754634
Drug: Eltrombopag and Diacerein
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
Trial: NCT04563871
Drug: 80mg Osimertinib
RxNorm normalized name: osimertinib 80 MG
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One tablet of 80mg Osimertinib for oral administration per day
Trial: NCT00559624
Drug: Acadesine
RxNorm normalized name: acadesine
DrugBank: Acadesine (DB04944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
Trial: NCT03467217
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype
Trial: NCT03467217
Drug: Placebo losartan capsule
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo losartan oral capsule
Trial: NCT01865669
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin, 10-10mol/L to 10-5mol/L
Trial: NCT00174967
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
Trial: NCT00174967
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
Trial: NCT00174967
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
Trial: NCT03937908
Drug: 2g Centella asiatica water extract product
RxNorm normalized name: Centella Asiatica Extract
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
Trial: NCT03937908
Drug: 4g Centella asiatica water extract product
RxNorm normalized name: Centella Asiatica Extract
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
Trial: NCT04238143
Drug: Sterile Normal Saline (IV Solution)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of cSVF in 500 cc Sterile Normal Saline (IV Solution)
Trial: NCT02416531
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
Trial: NCT03234153
Drug: Durvalumab (Imfinzi)
RxNorm normalized name: durvalumab Injection [Imfinzi]
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
Trial: NCT03234153
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
Trial: NCT00408148
Drug: Rimonabant
RxNorm normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: White film-coated, for oral administration containing 20 mg of active rimonabant
Trial: NCT01780935
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injections of 0.5 mg Ranibizumab
Trial: NCT02666287
Drug: BAT
RxNorm normalized name: RibaTab
DrugBank: Equine Botulinum Neurotoxin E Immune FAB2 (DB13897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.